Aeolus Pharmaceuticl
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the… Read more
Aeolus Pharmaceuticl (AOLS) - Net Assets
Latest net assets as of June 2017: $207.00K USD
Based on the latest financial reports, Aeolus Pharmaceuticl (AOLS) has net assets worth $207.00K USD as of June 2017.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($794.00K) and total liabilities ($587.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $207.00K |
| % of Total Assets | 26.07% |
| Annual Growth Rate | -11.51% |
| 5-Year Change | N/A |
| 10-Year Change | 170.76% |
| Growth Volatility | 122.55 |
Aeolus Pharmaceuticl - Net Assets Trend (1996–2016)
This chart illustrates how Aeolus Pharmaceuticl's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aeolus Pharmaceuticl (1996–2016)
The table below shows the annual net assets of Aeolus Pharmaceuticl from 1996 to 2016.
| Year | Net Assets | Change |
|---|---|---|
| 2016-09-30 | $3.19 Million | +478.11% |
| 2015-09-30 | $-845.00K | -153.31% |
| 2014-09-30 | $1.58 Million | +124.82% |
| 2013-09-30 | $705.00K | +103.47% |
| 2012-09-30 | $-20.34 Million | +12.57% |
| 2011-09-30 | $-23.26 Million | +13.00% |
| 2010-09-30 | $-26.74 Million | -2210.80% |
| 2009-09-30 | $-1.16 Million | -11.57% |
| 2008-09-30 | $-1.04 Million | -187.88% |
| 2007-09-30 | $1.18 Million | -30.87% |
| 2006-09-30 | $1.71 Million | +283.15% |
| 2005-09-30 | $-932.00K | -116.85% |
| 2004-09-30 | $5.53 Million | +132.39% |
| 2003-09-30 | $-17.08 Million | -17.95% |
| 2002-09-30 | $-14.48 Million | -356.42% |
| 2001-09-30 | $5.65 Million | +17.35% |
| 2000-09-30 | $4.81 Million | +26.63% |
| 1999-09-30 | $3.80 Million | -80.71% |
| 1998-09-30 | $19.70 Million | -25.66% |
| 1997-09-30 | $26.50 Million | -28.18% |
| 1996-09-30 | $36.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aeolus Pharmaceuticl's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18688800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2016)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.52 Million | 47.57% |
| Other Components | $191.86 Million | 6005.10% |
| Total Equity | $3.19 Million | 100.00% |
Aeolus Pharmaceuticl Competitors by Market Cap
The table below lists competitors of Aeolus Pharmaceuticl ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cycurion, Inc. Common Stock
PINK:CYCU
|
$4.70K |
|
Arras Minerals Corp.
OTCQB:ARRKF
|
$4.71K |
|
D. M. Textile Mills Limited
KAR:DMTX
|
$4.71K |
|
Nowigence Inc.
OTCQB:NOWG
|
$4.71K |
|
Kegalle Plantations PLC
CM:KGALN0000
|
$4.70K |
|
SIEVI CAPITAL (WE3.SG)
STU:WE3
|
$4.70K |
|
Bim Son Packing JSC
VN:BPC
|
$4.70K |
|
Union Andina de Cementos S.A.A.
LIM:UNACEMC1
|
$4.69K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aeolus Pharmaceuticl's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2015 to 2016, total equity changed from -845,000 to 3,195,000, a change of 4,040,000.
- Net loss of 3,558,000 reduced equity.
- Share repurchases of 2,005,000 reduced equity.
- Other factors increased equity by 9,603,000.
Equity Change Factors (2015 to 2016)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.56 Million | -111.36% |
| Share Repurchases | $2.00 Million | -62.75% |
| Other Changes | $9.60 Million | +300.56% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aeolus Pharmaceuticl's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-09-30 | $60.33 | $0.00 | x |
| 1997-09-30 | $37.96 | $0.00 | x |
| 1998-09-30 | $27.75 | $0.00 | x |
| 1999-09-30 | $5.19 | $0.00 | x |
| 2000-09-30 | $7.62 | $0.00 | x |
| 2001-09-30 | $6.86 | $0.00 | x |
| 2002-09-30 | $-11.17 | $0.00 | x |
| 2003-09-30 | $-12.51 | $0.00 | x |
| 2004-09-30 | $0.66 | $0.00 | x |
| 2005-09-30 | $-0.07 | $0.00 | x |
| 2006-09-30 | $0.09 | $0.00 | x |
| 2007-09-30 | $0.04 | $0.00 | x |
| 2008-09-30 | $-0.03 | $0.00 | x |
| 2009-09-30 | $-0.03 | $0.00 | x |
| 2010-09-30 | $-0.54 | $0.00 | x |
| 2011-09-30 | $-0.27 | $0.00 | x |
| 2012-09-30 | $-0.28 | $0.00 | x |
| 2013-09-30 | $0.01 | $0.00 | x |
| 2014-09-30 | $0.01 | $0.00 | x |
| 2015-09-30 | $-0.01 | $0.00 | x |
| 2016-09-30 | $0.02 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aeolus Pharmaceuticl utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -111.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -171.39%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.30x
- Recent ROE (-111.36%) is above the historical average (-127.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 3.31% | 24.00% | 0.13x | 1.07x | $-2.42 Million |
| 1997 | -67.17% | -445.00% | 0.10x | 1.45x | $-20.45 Million |
| 1998 | -96.95% | -313.11% | 0.22x | 1.41x | $-21.07 Million |
| 1999 | -515.79% | -933.33% | 0.26x | 2.11x | $-19.98 Million |
| 2000 | -138.51% | -6665.00% | 0.01x | 1.53x | $-7.15 Million |
| 2001 | -393.36% | -50484.09% | 0.01x | 1.53x | $-22.78 Million |
| 2002 | 0.00% | -13141.86% | 0.04x | 0.00x | $-9.85 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.27 Million |
| 2004 | -310.32% | -5628.52% | 0.04x | 1.42x | $-17.72 Million |
| 2005 | 0.00% | -2740.08% | 0.27x | 0.00x | $-6.81 Million |
| 2006 | -335.56% | -6226.09% | 0.03x | 2.08x | $-5.90 Million |
| 2007 | -256.27% | 0.00% | 0.00x | 1.64x | $-3.14 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.87 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.18 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.20 Million |
| 2011 | 0.00% | 6.20% | 2.11x | 0.00x | $2.62 Million |
| 2012 | 0.00% | 23.28% | 5.81x | 0.00x | $3.73 Million |
| 2013 | -455.04% | -81.67% | 2.00x | 2.79x | $-3.28 Million |
| 2014 | -5.05% | -0.83% | 2.69x | 2.26x | $-238.50K |
| 2015 | 0.00% | -84.47% | 1.75x | 0.00x | $-2.54 Million |
| 2016 | -111.36% | -171.39% | 0.50x | 1.30x | $-3.88 Million |
Industry Comparison
This section compares Aeolus Pharmaceuticl's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aeolus Pharmaceuticl (AOLS) | $207.00K | 3.31% | 2.84x | $4.70K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |